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Editorial Comment , 
Starting with Volume 156, 1979, the name of the «Zeitschrift für 
Immunitätsforschung» has been changed to 
«Immunobiology » 
The «Zeitschrift», founded in 1909 by Paul Ehrlich, was the first 
immunological journal to be published in the world. The journal has 
a long-lived reputation as being an important source of scientific 
information based on the contributions of famous immunologists. 
The increased use of English as the common scientific language has 
now prompted the Editorial Board to change the traditional Ger-
man title to «Immunobiology». With this title change the journal 
emphasizes its international character as a forum for the publication 
of a variety of different articles in the broad field of immunology. 
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Abstract 
Lyt T cell subsets involved in the generation of H-2 restricted and alloreactive cytotoxic 
effector cells were analysed using anti Lyt antisera. Our data show that Lyt 1, 2, 3 + T cells are 
required for the induction of primary and secondary H-2 restricted and TNP-specific killer 
cells. In contrast, primary and secondary H-2 restricted and virus-specific T effector cells were 
obtained from selected Lyt 2, 3 + T cell populations and were not dependent on the presence of 
Lyt 1, 2, 3 + T cells. Allogeneic responses to selected K, I , or D region differences were 
obtained only in the presence of Lyt 1, 2, 3 + T cells; yet alloreactive killer cells were effectively 
generated from selected Lyt 2, 3 + T cell populations deprived of Lyt 1, 2, 3^ T cells, when 
responder and stimulator cells differed at either K + D, K + I , I and D regions or in the entire 
H-2 region. 
Taken together, the results suggest that there is no qualitative difference between alloreactive 
and H-2 restricted cytotoxic responses in their requirements for particular Lyt T cell subsets. 
The findings indicate that the number of different antigenic determinants rather than their 
association with MHC self determinants is critical for the requirement of Lyt 1, 2, 3 + T cells 
during the sensitization phase. 
Introduction 
It is now well established that the effector functions of thymus derived 
lymphocytes involved in the regulation of the immune response are medi-
ated by T cell subpopulations. The classification of the T cell lineage into 
subsets was made possible by the discovery of cell surface markers. 
Using the Lyt alloantigen system, described by BOYSE and co-workers 
(1, 2), it has been demonstrated that T lymphocyte subsets with known 
functional capacities also show characteristic distribution patterns of these 
surface structures (3, 4, 5, 6). Current information suggests that in the 
mouse T cells expressing the Lyt 1 + , Lyt 2, 3" surface phenotype play an 
obligatory helper or accessory role in most immune responses (4, 5). In 
contrast, T cells which express the Lyt 1", Lyt 2, 3 + phenotype develop 
both the capacity to suppress immune responses as well as the ability to 
elicit alloreactive cytotoxic activity (5, 6, 7, 8). 
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However, it has recently been shown by CANTOR and BOYSE that the 
generation of H-2 restricted cytotoxic lymphocytes specific for T N P -
modified syngeneic cells requires the presence of Lyt 1, 2, 3 + cells in the 
induction phase (9). The authors suggested that the Lyt 1, 2, 3 + cells 
probably represent the killer cell precursor population but it is still possible 
that these cells represent the helper cell population involved in the genera-
tion of cytotoxic effector cells from Lyt 2, 3 + killer cell precursors. The 
finding by BURAKOFF et al. (10) that the H-2 restricted and TNP-specific 
cytotoxic activity generated from a cell mixture containing the Lyt 2, 3 + T 
cell subset from one strain and the unselected T cell population from the 
Lyt congenic partner was only abolished by anti-Lyt 2 antisera specific for 
the unselected T cell population, was interpreted in favour of Lyt 1, 2, 3 T 
cells consisting of H-2 restricted killer cell precursors. Similar requirements 
for Lyt 1, 2, 3 T cells were reported for the generation of H-2 restricted and 
virus specific cytotoxic lymphocytes (10), which implies that alloreactive 
and H-2 restricted killer cells are generated by different pathways. 
The data reported in this paper show that Lyt 1, 2, 3 + cells are required 
for the induction of some, but not all, H-2 restricted cytotoxic responses in 
vitro. 
Furthermore, we demonstrate that there is also a requirement for Lyt 1, 
2, 3 + T cells in the generation of alloreactive cytotoxic activity against 
M H C sub regions. 
Altogether, the presented data suggest that the differences seen for the 
induction requirements of H-2 restricted and alloreactive cytotoxic effector 
cells in their requirements for T cell subsets are quantitative rather than 
qualitative. 
Materials and Methods 
Mice 
6 to 12 week old male or female mice were used for the experiments. All strains used were 
bred in our own colony: C57B1/6, C57B1/10, B10.D2, B10.Br, B10.A, B10.A(2R), B10.A(4R), 
B10.AKM, Balb/c, C.B-17, ATL, and A.AL. All mice used for the generation of anti-Lyt 
antisera, B6-Lyt 1.1 congenic mice (Lyt phenotype 1.1, 2.2, 3.2), B6-Lyt 2.1 congenic mice 
(Lyt phenotype 1.2, 2.1, 3.2), B6-Lyt 2.1, 3.1 congenic mice (Lyt phenotype 1.2, 2.1, 3.1), as 
well as the CE F2 Lyt 1.2 homozygous, Lyt 2.1 homozygous and Lyt 3.2 homozygous 
animals, originally obtained by Dr. Shen and Dr. Boyse, were also maintained in our colony. 
Viruses 
Sendai virus (kindly provided by Dr. M.-G. Gething, ICRF, London) and influenza A virus 
(A/Victoria H 3 N 2 , kindly provided by Dr. Rott, Gießen) were grown in 10 day old 
embryonated chicken eggs. Harvesting and purification of virus was done as described 
previously (11). 
Immunizations and sensitizations 
Mice were injected i.p. with 100 haemagglutinating units (HAU) of infective virus. Lym-
phocytes from spleen and lymph nodes were removed 3-10 weeks afterwards and analyzed in 
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vitro. Mice were sensitized to TNP by skin painting with 30% picrvlchloride in acetone and 
the spleen cells were removed 7 days later. 
Media 
MLC's were performed in RPMI 1640 supplemented with L-glutamine (2 mM final 
concentration), streptomycine and penicillin (50 U/ml), Hepes buffer (25 mM final concentra-
tion), 2-mercaptoethanol (2 X 10"5 M) and 10% selected fetal calf serum. 
Tumor cells P-815 (H-2d) and RBL-5 (H-2b) tumor cells were grown in medium at a 
concentration of 2 X 105 cells/ml with medium change after every 48 hours. 
Antisera 
Anti-Thy 1.2 antiserum (AKR anti C3H) was kindly provided by Dr. B. RUBIN, Statens 
Seruminstitut, Copenhagen, Denmark. Anti-Lyt antisera were prepared as described by SHEN 
et al. (12). Briefly, anti-Lyt 1.2 antisera were prepared by injecting C3H/An mice with 
thymocytes from (C3H/An X CE)F2 mice homozygous for the Lyt 1.2 allele. Anti-Lyt 2.2 
antisera were prepared by injecting (C3H/An X B6/Lyt 2.1, 3.2)F1 hybrids with thymocytes 
from C57B1/6 mice. Anti-Lyt 3.2 antisera were prepared by injecting C58 mice with 
thymocytes from (C58 X CE)F2 mice homozygous for the Lyt 3.2 allele. After 1 subcutane-
ous injection of 50-100 X 106 donor thymocytes and three additional intraperitoneal injec-
tions of 50-100 X 106 donor thymocytes at 14 day intervals, each mouse was tested 
individually and those selected for further immunization were mice that produced good 
specific titers after removal of autoantibodies by absorption on thymocytes from the recipient 
strains. Selected mice were bled on days 7 and 10 after each inoculation and the sera from 
several bleedings were pooled and stored at — 70 °C. Prior to use the Lyt antisera were 
absorbed once on 100 X 108 thymus and lymph node cells from the recipients and the B6 
congenic strain (carrying the irrelevant Lyt allele) per ml undiluted antisera to remove 
autoantibodies. In a microcytotoxicity test the titer of anti-Lyt 1.2 was 1:250, the titer of anti-
Lyt 2.2 was 1:250 and the titer of anti-Lyt 3.2 was 1:500 on thymocytes of strain C57B1/6 after 
the removal of autoantibodies. Anti Lyt 1.2 antisera were negative on lymphocytes of B6/Lyt 
1.1 congenic mice, anti-Lyt 2.2 and anti-Lyt 3.2 antisera were negative on lymphocytes of B6 
Lyt 2.1, 3.1 congenic mice. The anti-Lyt 1.2 antisera as well as the anti-Lyt 2.2 antisera were 
used at a final dilution of 1:20. The anti-Lyt 3.2 antisera were used at a final dilution of 1:40. 
For treatment of lymphocytes with antisera and complement prior to in vitro stimulation 
30 X lOVml normal lymph node or spleen cells, or nylon wool purified splenic T cells were 
incubated with anti-Thy 1.2 antiserum (1:20 final dilution) or the appropriate anti-Lyt antisera 
in RPMI 5% fetal calf serum and incubated for 30 min at room temperature. Cells were 
centrifuged and resuspended in freshly thawed selected rabbit serum (dilution 1:10 to 1:12) as a 
source of complement in 5% FCS/RPMI and incubated for an additional period of 30 min at 
37 °C. The treatment of cells with anti-Lyt antisera and complement was repeated once to 
obtain highly purified Lyt subsets. Cytotoxic effector lymphocytes generated from lymph 
node or spleen cells or nylon wool purified T cells in 4-5 days MLR's were treated with Lyt 
antisera and complement as described above. 
In vitro generation of effector cells 
5 X 106 responder cells were incubated at 37 °C with 1 X 106 to 2.5 X 106 stimulator cells in 
2 ml in Linbro macrotiter plates (FB 16-24 TC) and incubated for 4-6 days in humidified air 
plus 5% C0 2 . Purified splenic T cells were obtained as described by JULIUS et al. (13). As 
stimulator cells, allogeneic B cells, obtained by treatment of spleen cells with anti-Thy 1.2 plus 
complement, TNP modified syngeneic spleen cells or syngeneic cells preincubated with viral 
antigens (10 ug Sendai virus, ß-propiolactone inactivated/106 cells) for 1 hour at 37 °C were 
used. 
Cell mediated lymphocytotoxicity assay and analysis of data 
Following the 5 day incubation period cytotoxic activity of effector cells was tested on either 
chromium labelled concanavalin A (Con A) spleen cell blasts or tumor cells. Con A blasts were 
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obtained by stimulating 12.5 X 106 spleen cells with 5 ug/ml Con A (Miles-Yeda, Ltd., Illinois 
60901, Code 79-002) in 6 ml media (2, 4) and incubated for 48 hours. Con A blasts and tumor 
cells were labelled with 3 ,chromium. 2 X 104 blast cells or 1 X 104 tumor cells were incubated 
for 4 hours at 37 °C with various numbers of cytotoxic T cells in 200 ul RPMI medium 
(containing 10% fetal calf serum and 0.1 mM Hepes buffer, final concentration) in round 
bottom microtiter plates (Linbro IS-MRC-96). Afterwards, the plates were spun for 5 minutes 
at 1500 rpm, 100 ul of the supernatant were removed, and the isotope released from the 5 1 Cr 
labelled target cells was counted. An aliquot of the target cells were frozen and thawed four 
times so that maximum 3 'Cr release could be determined. The percentage of 3 'Cr release from 
target cells was determined using triplicate samples and calculated by the following formula: 
5 1 Cr release by immune cells - 3 1Cr release by normal cells 
max. 
All measurements were performed in triplicate and the standard error of the mean was 
always less than 5%. 
% specific lysis = ^ : ^ : : j j-j X 100 
r ' ™ w Cr release - 'Cr release by normal cells 
Mixed lymphocyte culture 
Proliferative response of mixed lymphocyte cultures was tested by removing 100 ul from the 
bulk cultures and labelling with 3 H (thymidine) (The Radiochemical Center, Amersham 
Buchler, England, 2 Ci/nm) at 2 uCi/well for 12 hours. Specific incorporation was determined 
by substracting background responses of responder cells incubated with syngeneic irradiated 
cells. 
Results 
Generation of primary alloreactive and H-2 restricted cytotoxic lympho-
cytes from unselected and selected T cell populations 
In order to determine the Lyt phenotype of killer cell precursors in a 
primary response to alloantigen or N A D (new antigenic determinants) 
formed by T N P or Sendai virus on syngeneic cells, lymphocytes were 
pretreated with either anti-Lyt 1 or anti-Lyt 2, 3 antisera and complement. 
Thereafter, the treated cell populations were cultured either separately or as 
a 1:1 mixture of the two populations selected for Lyt 1 + or Lyt 2.3 + T cells, 
respectively with the sensitizing antigen. 
Figure 1 shows typical response patterns of unprimed splenic lympho-
cyte populations, either unselected or selected for Lyt T cell subsets and 
activated by allogeneic stimulators or syngeneic cells modified with T N P or 
Sendai virus respectively. B6 Lyt 2,3 + splenic T cells were able to mount a 
primary cytotoxic response to irradiated H-2 incompatible B10.D2 cells. 
The same population was unable to respond in a primary reaction to T N P 
haptenated syngeneic cells, even in the presence of Lyt 1 + helper cells, 
which augment the cytotoxic response of Lyt 2,3 + T cells to the alloantigen. 
Balb/c Lyt 2,3 + T cells as well as the mixture consisting of Lyt 1 + and Ly t 
2,3 + T cells were very efficient in eliciting a primary cytotoxic response to 
virus infected stimulators. The conditions for induction of a primary anti-
viral cytotoxic response and the distinction from a secondary response by 
functional criteria have been described in a preceding paper (11). The data 
depicted in Figure 1 clearly demonstrate that the presence of Lyt 1.2.3 + 
cells are only required for the formation of primary H-2 restricted and T N P 
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Fig. 1. Effect of pretreatment of CTL precursors specific for TNP, Sendai virus and allo-
antigens with anti Lyt antisera and complement prior to culture on the generation of primary 
cytolytic activity. 5 X 106 splenic responder cells (B6) were cultured for 5 days with 1 X 106 
irradiated syngeneic TNP conjugated spleen cells or 2.5 X 106 irradiated DBA spleen cells. 
5 X 106 nylon purified Balb/c T responder cells were cultivated in the presence of 1 ug 
inactivated Sendai virus/ml. Cultures were tested on day 5 for cytolytic activity on the relevant 
targets (see Materials and Methods) O—O, unselected population; A — A , selected for Lyt 1 + 
cells; •—selected for Lyt 2,3^ cells; • — A , selected for Lyt 1 and Lyt 2,3* cells (1:1). 
Numbers on the abscissa indicate effector to target ratio. 
specific cytotoxic lymphocytes but not for the generation of primary H-2 
restricted and virus specific or alloreactive cytotoxic lymphocytes. 
H-2 restricted as well as alloreactive cytotoxic effector cells generated to 
either T N P + self or viral + self or alloantigens respectively, were sensitive 
to treatment with anti-Thy 1.2 or anti-Lyt 2,3 but not to anti-Lyt 1 antisera 
and complement and are, therefore, Thy 1 + , Lyt 1", Lyt 2,3 + (data not 
shown). 
Generation of secondary H-2 restricted cytotoxic lymphocytes specific for 
TNP or viral antigen from unselected and selected T cell populations 
Since different T cell populations may participate in a secondary 
cytotoxic response in vitro we investigated the requirements for Lyt 
subpopulations in the formation of a secondary H-2 restricted cytotoxic 
response after priming in vivo. Secondary H-2 restricted T N P specific 
cytotoxic lymphocytes were generated by restimulation of splenic T cells 
from mice previously sensitized to T N P (skin painting) with irradiated and 
TNP modified syngeneic cells in vitro. Primed anti-TNP specific killer cell 
precursors are distinguishable from virgin precursor CTL's by functional 
criteria. We found that only primed T cells but not unprimed T cells 
enriched on nylon columns were able to mount an effective T N P specific 
cytolytic activity in vitro (M. SIMON, unpublished observation). Secondary 
H-2 restricted cytotoxic lymphocytes specific for influenza A (strain A 
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Victoria H3N2) , were obtained by restimulating nylon wool enriched 
splenic T cells in vitro from mice previously sensitized in vivo using virus 
infected cells as stimulators. Figure 2 summarizes the results of an experi-
ment in which nylon wool purified splenic T cells either unselected or 
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Fig. 2. Effect of pretreatment of unprimed alloreactive and primed TNP or primed influenza A 
virus specific lymphocytes with anti Lyt antisera and complement prior to the sensitization 
phase or prior to the effector phase on the generation and cytolytic activity of CTL's in vitro. 
5 X 106 TNP primed C.B-17 nylon purified T cells were incubated with 1 X 106 irradiated 
syngeneic TNP modified stimulator cells or with 2.5 X 106 irradiated AKR spleen cells. 
5 X 106 SV primed and nylon purified B10.D2 T cells were cultured in the presence of 1 jig 
inactivated Sendai virus/ml. Cultures were tested on day 5 in the 5 , Cr release assay as described 
in Materials and Methods. O—O unselected populations; A—A selected for Lyt 1 + cells; 
selected for Lyt 2,3+ cells; • — • selected for Lyt 1 + and Lyt 2,3 + cells (1:1); • — • cells 
treated with aThy 1 and complement. 
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syngeneic cells or co-cultured with allogeneic stimulator cells from strain 
AKR. In addition, the secondary responses of unselected T lymphocytes as 
well as Lyt 1 + and/or Lyt 2,3 + T cells from strain B10.D2 to influenza A 
modified syngeneic cells are depicted in the same Figure 2. Secondary T N P -
specific killer cells were only generated from unselected populations and 
were not obtained from Lyt 2,3 + T cells alone. In most experiments the 
mixed population comprised of Lyt 1 + and Lyt 2,3^" T cells was also 
ineffective in generating T N P specific cytolytic effector cells. In contrast, 
the mixed population was very efficient in eliciting effective responses to 
viral- or alloantigens. As seen before, primary alloreactivity was also 
obtained from Lyt 2,3 + T cells in the absence of Lyt 1 + T cells. Thus, as for 
the primary cytotoxic response Lyt 1,2,3+ T cells are also involved in the 
generation of secondary cytotoxic lymphocytes to TNP-coupled syngeneic 
stimulator cells. The same population is not required during the induction 
of secondary responses to influenza A viral antigens (also found in secon-
dary responses to Sendai virus; data not shown). Figure 2 also compiles data 
showing that alloreactive as well as secondary H-2 restricted cytotoxic 
effector cells specific for T N P or viral antigen are Lyt 1" Lyt 2,3 + . 
Requirements for Lyt T cell subsets in the generation of cytotoxic responses 
to antigens encoded by different regions within the H-2 complex 
The finding that there is a different requirement for Lyt 1,2,3 + cells in the 
generation of H-2 restricted cytotoxic T cells to different modifying 
antigens prompted us to study the participation of Lyt T cell subsets in the 
induction of alloreactive T cells specific for selected M H C determinants. 
Lymph node cells from different mouse strains were pretreated with anti-
Lyt 1 or anti-Lyt 2,3 antisera and complement. Responder populations 
selected for T cell subsets were co-cultured with anti-Thy 1 plus comple-
ment treated and x-irradiated spleen cells (B cells) as stimulators. The latter 
treatment was done to avoid a possible stimulating effect of the irradiated 
allogeneic T cell population (14). Responder and stimulator cells differed at 
either the K, I or D regions alone or were incompatible at either the K and I , 
K and D , I and D or the whole M H C region, respectively. The data 
presented in Figure 3 reveal that Lyt 1,2,3+ T cells are essential for the 
formation of cytotoxic responses to either K (ATL anti A . A L ) , D (BIO.A 
anti BIO.A [2R] or I (ATL anti A T H ) region differences alone. This is 
abvious from the fact that neither the Lyt 2,3 + T cell subset alone nor the 
mixture containing Ly t 1 + and Lyt 2,3 + T cells are able to mount an 
effective response to the appropriate antigen. In contrast, Lyt 1,2,3 + T cells 
were not required for the generation of cytotoxic activities when responder 
and stimulator cells differed at either the K and I (BIO anti B10.A [4R]), the 
K and the D (ATL anti B10.AKM), the I and D regions (B10.Br anti B10.A 
[4R]) or in the whole M H C complex (B10.Br anti B6), respectively. In the 
latter three combinations cytotoxic lymphocytes were obtained from either 
Lyt 2,3 + T cells alone or in mixed populations consisting, in addition, Lyt 
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Fig. 3. Effect of pretrcatment of alloreactive CTL precursors with anti Lyt antisera and 
complement prior to culture on the in vitro generation of cytolytic activity. 5 X 106 lymph 
node responder cells were cultured with 2.5 X 106 irradiated stimulator cells (B cells). Effector 
cells were tested on day 5 in a Cr release assay. O—O unselected population; A — A selected 
for Lyt 1 + cells; • — • selected for Lyt 1,2,3 + cells; • — • selected for Lyt 1 + and Lyt 2,3 + 
cells. Numbers on the abscissa indicate the number of responder cells ( X 106) cultured on day 
0, the descendents of which are tested on 2 X 104 target cells. 
1 + T cells. In the experiment depicted in Figure 3, aliquots of the same A T L 
responder Lyt T cell subsets were used to react to either K, I or K plus D 
region differences. Thus, the lack of generation of cytolytic activity to K or 
I region differences alone from the mixed population containing Lyt 1 + and 
Lyt 2,3 + T cells could not be due to unspecific removal of all Lyt 2,3 killer 
cell precursors. 
Table 1. MHC difference between responder and stimulator cells A cpma) 
Responding cell K D I-A, S, G K, I-A K, D I-B, S, G, D 
population d 3 d 4 d 3 d 4 d 3 d 4 d 3 d 4 d 3 d 4 d 3 d 4 
untreated (C) 24,686 n.d. 14,308 18,970 49,133 37,117 54,090 n.d. 49,964 43,012 n.d. 26,565 
Lyt 2,3 + 2,913 n.d. 5,208 4,627 14,303 9,819 8,576 20,623 6,669 38,997 n.d. 13,780 
Lyt 1 + 1,266 n.d. 8,903 16,168 18,443 12,487 29,162 84,321 11,230 38,485 n.d. 18,288 
Lyt 1+ + Lyt 2, 3 + 4,460 n.d. 10,420 19,850 17,406 11,747 23,014 64,401 28,202 65,207 n.d. 24,120 
a) A = Mean [ 3 H] thymidine uptake for allogeneic combination - mean [ 3 H] thymidine uptake for syngeneic combination. 
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Responder cells from the same cultures, which were tested for generation 
of killer cells, were also studied for their proliferative responses. The data 
are summarized in Table 1. As already shown by several authors (4, 5,15) it 
was found that in MLC's differing at either the entire or parts of the H-2 
complex pretreatment of lymph node T cells with anti-Lyt 1 antiserum plus 
complement removed the majority of the proliferating cells in all strain 
combinations tested. In the combined mixture of Lyt 1 + and Lyt 2,3 + T 
cells the proliferative responses were restored more or less in most strain 
combinations. In the strain combination A T L anti A . A L , where responder 
and stimulator differ only in the K region, the proliferative response 
remained low and no cytotoxic lymphocytes were generated from the T cell 
population consisting of Ly t 1 + and Lyt 2,3 + T cells. Similar results were 
obtained in studies of T cell responses to mutant H-2 K and H-2 D 
alloantigens in which the proliferation was shown to be dependent on Lyt 
1,2+ cells (16). One would assume that H-2 K end antigens, when presented 
as the only determinants on stimulator cells, are only able to induce 
responses in Lyt 1,2,3+ but not in Lyt 1 + or Lyt 2,3 + T cells. However, in 
two strain combinations where responder and stimulator cells differ at 
either only the I region or only the D region of the major histocompatibility 
complex Lyt 1 + T cells could be activated. Nevertheless, there was no 
generation of cytotoxic lymphocytes against either I region or D region 
determinants from cell mixtures containing Lyt 1 + and Lyt 2,3 + T cells. 
Since the proliferating Lyt 1 + T cells are not able to evoke cytotoxic 
lymphocytes from the Lyt 2,3 + cell pool this finding suggests that the 
majority of killer cell precursors specific for I or D determinants reside in 
the Lyt 1,2,3+ T cell population. 
Discussion 
The aim of this study was to define the T cell subsets required for the 
generation of cytotoxic T effector cells specific for alloantigen or new 
antigenic determinants ( N A D ) formed by T N P or viral antigens on 
syngeneic cells. It is evident from the data presented that a strict distinction 
between alloreactive and H-2 restricted cytotoxic responses on the basis of 
their requirements for distinct Lyt T cell subsets during the sensitization 
phase is not justified. We have shown that Lyt 1,2,3 + T cells are necessary 
to generate H-2 restricted cytotoxic lymphocytes specific for T N P and for 
the development of alloreactive cytotoxic responses to K, I or D differences 
alone (i.e. when responder and stimulator cells differ at either only the K, I 
or D region, respectively); yet Lyt 1,2,3 + T cells are not required during the 
induction phase of H-2 restricted and virus-specific cytotoxic lymphocytes 
or for the generation of alloreactive killer cells when responder and 
stimulator cells differ at either both the K and D , K and I , I and D or the 
whole M H C region. 
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Our data on primary T N P specific cytotoxic responses are in agreement 
with the experiments reported by C A N T O R and B O Y S E (9) and B U R A K O F F 
et al. (10). We extended these studies and found in most experiments that 
Lyt 1,2,3 + T cells are also required in a secondary response to T N P -
modified target cells. Similar requirements for Lyt 1,2,3 + T cells in the 
generation of H-2 restricted CTL's have also been found in in vitro 
secondary responses to the male specific antigen H - Y (M. M . Simon, 
unpublished and [17]). This is consistent with the view that different Ly t T 
cell subsets discriminate between foreign non M H C antigens and alloanti-
gens. The possibility of a separation of precursor killer cells into two 
subsets based on alio versus non-MHC reactivity has originally been 
described by C A N T O R and B O Y S E (9). Their assumption that killer cell 
precursors responsible for H-2 restricted cytotoxic responses reside with in 
the Lyt 1,2,3+ cell pool while the alloreactive killer cell precursors are 
comprised in the Lyt 2,3 + T cell population was substantiated by studies of 
B U R A K O F F et al. (10) on the generation of TNP-specific killer cells. I t was 
found that in mixed lymphocyte populations consisting of Lyt 1,2,3+ and 
Lyt 2,3 + subsets derived from Lyt 2,3 congenic strains H-2 restricted 
effector cells expressed the Lyt 2,3 phenotype of Lyt 1,2,3 + cells present in 
the unselected T cell pool. The data were interpreted to mean that T cell 
clones with specificity for self plus X determinants are predominantly 
found in the Lyt 1,2,3+ but not in the Lyt 2,3 + subset. 
We have now demonstrated that Lyt 1,2,3+ T cells are not required for 
the induction of both primary and secondary virus specific cytotoxic 
responses. The conditions which allow separation of primary versus 
secondary SV specific cytotoxic responses have been described in a preced-
ing paper (11). B U R A K O F F et al. (10) reported results suggesting that Lyt 
1,2,3 + T cells are mainly involved in the formation of Sendai virus specific 
cytotoxic lymphocytes. Unfortunately, it was not indicated by the authors 
whether the cytotoxic activity measured was a primary or secondary anti-
viral response. We cannot at the moment explain the discrepancy between 
our and their findings, but it is unlikely that this is due to different mouse 
strains tested since we found similar requirements for Ly t subsets in several 
strains investigated. 
The differences seen in the induction requirements for primary and 
secondary H-2 restricted T N P specific versus H-2 restricted virus specific 
cytotoxic responses may be explained in quantitative terms: H-2 restricted 
TNP-specific killer and virus-specific killer cell precursors reside in both 
the Lyt 1,2,3 + and the Lyt 2,3 + T cell pool but the number of virus specific 
cell clones is higher within the Lyt 2,3 + subset because of more frequent 
exposition of lymphocytes with possibly crossreactive viral antigens as 
compared to TNP determinants during ontogeny. Thus, the inability to 
generate primary and secondary T N P specific CTL's from the Lyt 2,3 + 
pool would be due to the small number of antigen specific clones, present in 
this population, which cannot be detected in the assay system. I t is even 
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possible that similar numbers of T N P or virus specific T cell clones reside 
within the Lyt 2,3 cell pool yet only virus specific killer cells exceed a 
minimum threshold level by mitogenic activity elicited by the virus (11), 
which helps to expand the antigen specific T cell clones. On the other hand 
one could visualize a qualitative difference of the two types of antigens 
resulting in different pathways of activation. 
Our data on the generation of cytotoxic responses to distinct alloantigens 
also revealed two patterns of participating Ly t subsets similar to that 
described for H-2 restricted responses. We found that Lyt 1,2,3 T cells are 
essential for the induction of alloreactive cytotoxic responses to K, I or D 
differences alone, thus extending results previously described by B A C H and 
ALTER (15) for mixed lymphocyte reactions in which the responses of Lyt 
subsets to H-2 D alloantigens were determined. In contrast, when respon-
der and stimulator differed in more than one region of the M H C complex, 
i.e. the K + I , K + D , I + D , or K, I and D regions respectively, we 
observed a generation of alloreactive killer cells from Lyt 2,3 + T cells in the 
absence of Lyt 1,2,3+ T cells. 
There are several possibilities to explain the constraints for Lyt 1,2,3 + T 
cells during the induction of alloreactive responses to selected M H C region 
determinants: 
a) From unpublished data we know that unprimed Lyt 2,3 + T cells 
contain killer cell precursors with specificities for either K or D region 
determinants since cytotoxic lymphocytes specific for both determinants 
are easily generated from the same T cell pool when responder and 
stimulator cells differ in more than one M H C region (M. M . Simon, 
unpublished). Thus, the inability of the selected Lyt 2,3 + T cells to respond 
to selected regions of the M H C cannot be due to the lack of the relevant T 
cell clones within this population. Therefore, other factors must control the 
response of Lyt 2,3 + T cells to selected M H C antigens. 
b) Determinants encoded by only one subregion of the H-2 complex may 
fail, perhaps due to suppressive mechanisms to induce a cytotoxic response 
from the Lyt 2,3 + T cells which are specific for these determinants. 
c) Help provided by Lyt 1 + T cells may be not sufficient and a fraction of 
the Ly t 1,2,3 cell pool provide additional help. 
d) Help provided by additional antigenic determinants could be operative 
during the generation of alloreactive killer cells from the Lyt 2,3 subset and 
is absent when only antigens encoded by one single M H C subregion is 
presented during the induction phase. This would be similar to the mechan-
isms described as intermolecular help by Lake and Mitchison (18, 19). They 
found that antigens encoded by only one M H C region are unable to initiate 
a humoral immune response unless additional M H C differences are present 
in the system. 
e) Qualitative differences of the antigenic determinants may govern the 
requirement for Lyt 1,2,3+ T cells. Bach and Alter proposed that the I 
region is an important control element which helps to determine which 
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pathway of T lymphocyte differentiation wi l l proceed in any particular 
situation (15). This is not easily reconciled with our data. In MLC's with 
responder and stimulator cells differing at the K + D , K + I or only at the I 
region we found no correlation between I region identity of responder and 
stimulator and requirement for Lyt 1,2,3 + T cells for killer cell induction. 
f) Self restricted recognition of selected alloantigenic K, I or D products 
may result in the participation of Ly t 1,2,3 + T cells. This is not very likely 
since it was found by Epstein and Cohn (20), Klein et al. (21), and Billings 
et al. (22), that K, I , or D determinants are not recognized in a H-2 
restricted manner, at least during the effector phase. 
Altogether, our findings cast doubt on the simplistic model that different 
T cell subsets give rise to alio- or foreign non H-2 antigen specific effector 
cells. The data are compatible wi th the view that H-2 restricted as well as 
alloreactive precursor killer cells reside within the Lyt 1,2,3 and the Lyt 2,3 
cell pool and can be generated from both T cell pools under appropriate 
conditions. This is also substantiated by our findings that in unselected T 
cell populations consisting of Ly t 1,2,3 and Lyt 2,3 lymphocytes H-2 
restricted as well as alloreactive cytotoxic activity is generated from the Lyt 
1,2,3 T cell pool (M. M . Simon, manuscript in preparation). This does not, 
however, exclude the possibility that different T cell sets within each Lyt 
subpopulation show preferential association with one (alio-) or the other 
type of antigen (X + M H C self). Since Lyt subsets do not distinguish 
between alio- versus foreign non M H C antigens in the generation of 
cytotoxic responses other factors like the number and regulatory influence 
of different antigenic determinants ( M H C and non M H C ) and/or their 
mitogenicity must be involved in the selection of Lyt T cell subsets required 
to elicit the appropriate cytolytic activity. 
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